Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche: luci e ombre

1. Gortani G, Valencic E, Tommasini A, Lepore L. I farmaci delle malattie infiammatorie croniche: dall’empirismo alla medicina molecolare. Medico e Bambino 2007;26:381-5. 2. Not T, Buratti E, Berti I, Trevisiol C, Neri E, Tommasini A. Le citochine: da mediatori della flogosi a bersaglio della terapia. Medico e Bambino 1998;17:103-7. 3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. 4. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763- 9. 5. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population- based study. Arthritis Rheum 2006;54: 54-9. 6. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004;36:342-7. 7. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 2007;13: 424-30. 8. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011;52:31-7. 9. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:1124-9. 10. Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment- resistant pediatric Crohn’ disease. Dig Dis Sci 2007;52:3329-33. 11. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther 2011;33: 243-50. 12. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011;38:2218-23. 13. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics 2011;29:387-401. 14. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iiiiv, xi-xiii,1-229. 15. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294:1671-87. 16. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46:187-208. 17. Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106:981-7. 18. Boeyer SL, Roettcher PA, Higgins GC, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003;30:394-400. 19. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58:1496-504. 20. Prince FH, Twilt M, ten Cate R, et al. Longterm follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68:635-41. 21. Prince FH, Geerdink LM, Borsboom GJ, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69: 138-42. 22. Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticularcourse juvenile idiopathic arthritis. Rheumatology (Oxford) 2010;49:1550-8. 23. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3259-64. 24. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92. 25. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804. 26. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25. 27. Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 2010;28:919-22. 28. Tse SM, Burgos-Vargas R, Laxer RM. Antitumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005;52:2103-8. 29. Otten MH, Prince FH, Ten Cate R, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis 2011;70:337-40. 30. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010;157:960-6. 31. Cantarini L, Rigante D, Lucherini OM, et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 2010;23:701-7. 32. Pessler F, Monash B, Rettig P, Forbes B, Kreiger PA, Cron RQ. Sjögren syndrome in a child: favorable response of the arthritis to TNF alpha blockade. Clin Rheumatol 2006;25: 746-8. 33. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behçet’s disease. Int J Immunopathol Pharmacol 2009;22:551-5. 34. Marchetti F, Barbi E, Tommasini A, Oretti C, Ventura A. Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol 2004;22:791-2. 35. Topaloğlu R, Ayaz NA, Waterham HR, Yüce A, Gumruk F, Sanal O. Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol 2008;27:1317-20. 36. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: A randomised, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94. 37. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, doublemasked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53: 18-23. 38. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42. 39. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863-73. 40. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin 2011;27:651-62. 41. Hyams JS, Lerer T, Griffiths A, et al. Longterm outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 2009;15:816-22. 42. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49:183-90. 43. de Ridder L, Benninga MA, Taminiau JA, Hommes DW. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;43:388-90. 44. Lee JS, Lee JH, Lee JH, et al. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16:1776-81. 45.Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2008;46:293-8. 46. Duricova D, Pedersen N, Lenicek M, et al. Infliximab dependency in children with Crohn’s disease. Aliment Pharmacol Ther 2009;29:792-9. 47. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30. 48. Cucchiara S, Escher JC, Hildebrand H, et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48:257-67. 49. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134: 1861-8. 50. Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn’s disease. Value Health 2010;13: 188-95. 51. Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2011;34:181-7. 52. Ruperto N, Lovell DJ, Cuttica R, et al.; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56: 3096-106. 53. Ruperto N, Lovell DJ, Cuttica R, et al.; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular- course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22. 54. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhoodrefractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011;63:612-8. 55. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22. 56. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin- resistant Kawasaki disease. J Pediatr 2008; 153:833-8. 57. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011;158:644-9. 58. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008;46:212-5. 59. Wilkinson NM, Erendzhinova E, Zeft A, Cabral DA. Infliximab as rescue therapy in three cases of paediatric Wegener’s granulomatosis. Rheumatology 2006;45:1047-8. 60. Filocamo G, Buoncompagni A, Viola S, et al. Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr 2008;153:432-4. 61. Nozawa T, Hara R, Kinoshita J, et al. Infliximab for a girl with refractory pyoderma gangrenosum. Nihon Rinsho Meneki Gakkai Kaishi 2008;31:454-9. 62. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008;47:877-80. 63. Yüksel S, Yalçinkaya F, Acar B, Ozçakar ZB, Oztürk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology 2006;45:1307-8. 64. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91. 65. Castro M, Papadatou B, Ceriati E, et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg 2007;392:161-4. 66. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis 2008;40:S260-4. 67. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 68. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 2008;42:875-9. 69. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010;105:1430-6. 70. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm272997.htm. 71. Lovell DJ, Ruperto N, Goodman S, et al.; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20. 72. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009;28:985-8. 73. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008;47:339-44. 74. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 2009;23:1868- 70. 75. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol 2009;104:3042-9. 76. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol 2009;104:2566-71. 77. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7. 78. Chang J, Girgis L. Clinical use of anti-TNFalpha biological agents: a guide for GPs. Aust Fam Physician 2007;36:1035-8. 79. Lahdenne P, Wikström AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken) 2010;62:785-90. 80. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005;11:442-6. 81. Rutgheerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006;23:451-63. 82. Lin J, Ziring D, Desai S, et al. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. 83. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704-12. 84. McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18. 85. Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011;10:563-8. 86. Pastore S, Londero M, Gortani G, et al. Infliximab- related vasculitis in patients affected by ulcerative colitis. J Pediatr Gastroenterol Nutr 2010;51:226-8. 87. Williams VL, Cohen PR. TNF alpha antagonist- induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-25. 88. Leger S, Etienne M, Duval-Modeste AB, Roussel A, Caron F, Thiberville L. Interstitial pneumonia after infliximab therapy for psoriasis. Ann Dermatol Venereol 2011;138:499- 503. 89. Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, Tsikouras AN, Potamianos S. Emergence of Crohn’s disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence? J Gastrointestin Liver Dis 2010;19:342. 90. Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis 2011;5:157-61. 91. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61. 92. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou- Gertsi P, Chronopoulou E, Trachana M. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine 2008; 42:293-7. 93. Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008;14:5523-7.